glipizide has been researched along with Obesity in 18 studies
Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.
glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy and long-term effects of glipizide treatment on glucose and insulin metabolism in individuals with impaired glucose tolerance (IGT)." | 9.12 | Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance. ( Ehrnström, B; Eriksson, JG; Groop, L; Lehtovirta, M; Salmela, S, 2006) |
| "Insulin-resistant, obesity-prone mice (KK strain) were treated with pioglitazone, placebo, or the sulfonylurea compound, glipizide, for 2." | 7.73 | Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. ( Bodary, PF; Eitzman, DT; Jongeward, KL; King, SA; Vargas, FB; Wickenheiser, KJ, 2005) |
| "Glipizide dosages were titrated to achieve specified therapeutic goals or a maximum daily dose of 40 mg." | 6.68 | The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. ( Ducharme, MP; Halapy, H; Jaber, LA, 1996) |
| "Thirty one obese subjects, 12 with non insulin dependent diabetes mellitus (NIDDM), 9 with impaired glucose tolerance (IGT) and 10 with normal glucose tolerance (NGT) each underwent four OGTTS (75 g), at 1 week intervals, after administration in random order of placebo or glipizide 0." | 6.67 | Acute effect of glipizide on glucose tolerance in obesity and diabetes mellitus (NIDDM). ( Perfetti, MG; Pontiroli, AE; Pozza, G, 1991) |
| "To assess the efficacy and long-term effects of glipizide treatment on glucose and insulin metabolism in individuals with impaired glucose tolerance (IGT)." | 5.12 | Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance. ( Ehrnström, B; Eriksson, JG; Groop, L; Lehtovirta, M; Salmela, S, 2006) |
| "This study was designed to compare the efficacy of acute premeal administration of glipizide versus nateglinide in controlling postprandial hyperglycemia in subjects with non-insulin-requiring type 2 diabetes." | 5.10 | Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues. ( Burge, MR; Carroll, MF; Izard, A; Riboni, K; Schade, DS, 2002) |
| "The addition of sibutramine to oral hypoglycemic therapy resulted in significant weight loss and improvement in metabolic parameters in this patient group." | 5.09 | Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. ( Ertorer, EM; Gokcel, A; Guvener, N; Karakose, H; Tanaci, N; Tutuncu, NB, 2001) |
| "Insulin-resistant, obesity-prone mice (KK strain) were treated with pioglitazone, placebo, or the sulfonylurea compound, glipizide, for 2." | 3.73 | Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. ( Bodary, PF; Eitzman, DT; Jongeward, KL; King, SA; Vargas, FB; Wickenheiser, KJ, 2005) |
| " Chronic administration of glipizide GITS attenuated serum glucose responses to oral glucose challenge at 12 and 24 months when compared to baseline (0 months)." | 2.71 | Beneficial metabolic effects of chronic glipizide in obese African Americans with impaired glucose tolerance: implications for primary prevention of type 2 diabetes. ( Gaillard, T; Osei, K; Rhinesmith, S; Schuster, D, 2004) |
| "Glipizide dosages were titrated to achieve specified therapeutic goals or a maximum daily dose of 40 mg." | 2.68 | The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. ( Ducharme, MP; Halapy, H; Jaber, LA, 1996) |
| "Thirty one obese subjects, 12 with non insulin dependent diabetes mellitus (NIDDM), 9 with impaired glucose tolerance (IGT) and 10 with normal glucose tolerance (NGT) each underwent four OGTTS (75 g), at 1 week intervals, after administration in random order of placebo or glipizide 0." | 2.67 | Acute effect of glipizide on glucose tolerance in obesity and diabetes mellitus (NIDDM). ( Perfetti, MG; Pontiroli, AE; Pozza, G, 1991) |
| "Weight loss was maintained throughout the study, which lasted 24 weeks." | 1.28 | Relationships between the amount of weight loss and post-heparin lipoprotein lipase activity in patients with type II diabetes. ( Darga, LL; Holden, JH; Jen, KL; Kasim, SE; Khilnani, S; Lucas, CP; Patton, S, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (27.78) | 18.7374 |
| 1990's | 6 (33.33) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carroll, MF | 1 |
| Izard, A | 1 |
| Riboni, K | 1 |
| Burge, MR | 1 |
| Schade, DS | 1 |
| Osei, K | 1 |
| Rhinesmith, S | 1 |
| Gaillard, T | 1 |
| Schuster, D | 1 |
| Bodary, PF | 1 |
| Vargas, FB | 1 |
| King, SA | 1 |
| Jongeward, KL | 1 |
| Wickenheiser, KJ | 1 |
| Eitzman, DT | 1 |
| Eriksson, JG | 1 |
| Lehtovirta, M | 1 |
| Ehrnström, B | 1 |
| Salmela, S | 1 |
| Groop, L | 2 |
| Goldberg, RB | 1 |
| Holman, R | 1 |
| Drucker, DJ | 1 |
| Miller, JL | 1 |
| Salman, K | 1 |
| Shulman, LH | 1 |
| Rose, LI | 1 |
| Jaber, LA | 1 |
| Ducharme, MP | 1 |
| Halapy, H | 1 |
| Riddle, MC | 1 |
| McDaniel, PA | 1 |
| Tive, LA | 1 |
| Gokcel, A | 1 |
| Karakose, H | 1 |
| Ertorer, EM | 1 |
| Tanaci, N | 1 |
| Tutuncu, NB | 1 |
| Guvener, N | 1 |
| Martin, G | 1 |
| Rand, J | 1 |
| Dowey, KE | 1 |
| Grant, AP | 1 |
| Hayes, JR | 1 |
| Patsch, W | 1 |
| Sailer, S | 1 |
| Braunsteiner, H | 1 |
| Pontiroli, AE | 2 |
| Perfetti, MG | 2 |
| Pozza, G | 2 |
| Kasim, SE | 1 |
| Darga, LL | 1 |
| Holden, JH | 1 |
| Khilnani, S | 1 |
| Patton, S | 1 |
| Jen, KL | 1 |
| Lucas, CP | 1 |
| Salo, S | 1 |
| Cederholm, J | 1 |
| Wibell, L | 1 |
| Liu, GC | 1 |
| Coulston, AM | 1 |
| Lardinois, CK | 1 |
| Hollenbeck, CB | 1 |
| Moore, JG | 1 |
| Reaven, GM | 1 |
1 review available for glipizide and Obesity
| Article | Year |
|---|---|
Current understanding of feline diabetes: part 2, treatment.
Topics: Animals; Blood Glucose; Body Weight; Cat Diseases; Cats; Diabetes Complications; Diabetes Mellitus; | 2000 |
10 trials available for glipizide and Obesity
| Article | Year |
|---|---|
Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.
Topics: C-Peptide; Cross-Over Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glipizide; Huma | 2002 |
Beneficial metabolic effects of chronic glipizide in obese African Americans with impaired glucose tolerance: implications for primary prevention of type 2 diabetes.
Topics: Adult; Black or African American; Blood Glucose; Body Composition; C-Peptide; Diabetes Mellitus, Typ | 2004 |
Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Fam | 2006 |
The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus.
Topics: Biological Availability; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glipizide; Hum | 1996 |
Glipizide-GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Me | 1997 |
Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control.
Topics: Appetite Depressants; Blood Glucose; Cholesterol; Cyclobutanes; Diabetes Mellitus; Double-Blind Meth | 2001 |
Improvement of glucose tolerance by minimal doses of glipizide in obese subjects with different degrees of glucose intolerance.
Topics: Blood Glucose; Female; Glipizide; Glucose Tolerance Test; Humans; Male; Obesity; Risk Factors | 1992 |
Acute effect of glipizide on glucose tolerance in obesity and diabetes mellitus (NIDDM).
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glipizide; Glucose; Glucose Toler | 1991 |
Combination of two sulfonylureas. Does it make sense.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, | 1988 |
Moderate weight loss and sulfonylurea treatment of non-insulin-dependent diabetes mellitus. Combined effects.
Topics: Blood Glucose; Body Weight; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Reducing; Fa | 1985 |
7 other studies available for glipizide and Obesity
| Article | Year |
|---|---|
Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance.
Topics: Animals; Carotid Arteries; Disease Models, Animal; Drug Evaluation, Preclinical; Glipizide; Insulin | 2005 |
Clinical decisions. Management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gl | 2008 |
Bedtime insulin added to daytime sulfonylureas improves glycemic control in uncontrolled type II diabetes.
Topics: Adult; Aged; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glipizide; Gly | 1993 |
Glipizide evaluation after a one year trial in maturity onset diabetics.
Topics: Aged; Diabetes Mellitus; Drug Evaluation; Glipizide; Humans; Middle Aged; Obesity; Sulfonylurea Comp | 1979 |
[The effect of Glipizide on the blood glucose and insulin in non-ketotic diabetes mellitus (author's transl)].
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Glipizide; Humans; Hyperlipidemias; Insulin; Insulin | 1976 |
Relationships between the amount of weight loss and post-heparin lipoprotein lipase activity in patients with type II diabetes.
Topics: Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mel | 1991 |
The impact of treatment on insulin release and relative peripheral resistance during the oral glucose tolerance test. A study of noninsulin-dependent diabetes mellitus and glucose intolerance.
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Exercise Therapy; Female; Glip | 1986 |